Search
Filters
Clear All
  • 28

Phase

  • 1
  • 2
  • 2
  • 3
  • 17
  • 24
  • 23

Found 28 Leukemia trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

S
Sandeep Batra, MD
1-25 years
All genders
Phase 3
Interventional
This phase III trial studies whether inotuzumab ozogamicin added to post-inductionhemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improvesutcomes. This trial also studies the outcomes of patients with mixed phenotype acuteukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy withoutuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal …
Learn More

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

S
Sandeep Batra, MD
All genders
Interventional
This study aims to use clinical and biological characteristics of acute leukemias to screengibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treaty provide information about the patient's leukemia that is important when deciding …
Learn More

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

S
Sandeep Batra, MD
1-30 years
All genders
This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia that is likely to come back or spread.
Learn More

A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

A
April Rahrig, MD
3-30 years
All genders
Phase 1/2
Interventional
To determine the recommended phase 2 dose (RP2D) of vorinostat in children, adolescents and young adults following allogeneic HCT. Eligibility:A prospective patient for allogeneic BMT for malignant hematologic conditions Ages 3-30 Diagnoses include:Acute Leukemia in remissionChronic Myeologenous Leukemia (CML)  Myelodysplastic syndrome (MDS) Additonal criteria must be met based on determination …
Learn More

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

S
Sandeep Batra, MD
24-18 years
All genders
Phase 2
Interventional
This trial studies the side effects of enasidenib and to see how well it works in treatingwith acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractory). Patients must also have a specific genetic change, also called a mutation, in a …
Learn More

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

T
Toshihiro Onishi, MD
6-21 years
All genders
Phase 3
Interventional
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) usinghed related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) ing children, adolescents, and young adults with acute leukemia or myelodysplasticyndrome (MDS). HCT is considered standard of care treatment for patients with high-riskute leukemia and MDS. In HCT, patients are …
Learn More

A Phase 2 Study of the MEK Inhibitor Trametinib in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

S
Sandeep Batra, MD
All genders
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment.
Learn More

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

S
S. Hamid Sayer, MD
18-60 years
All genders
This is a phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation.
Learn More

Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant (EXCEL)

T
Toshihiro Onishi, MD
All genders
Phase 2
Interventional
This is a Phase II pilot study to determine the efficacy of three fixed dose (1 x 108/kg)usions of ex-vivo expanded human leukocyte antigen (HLA)-haploidentical donor natural killer (NK) cells (haploNK) in children and young adults with high risk acute myeloidukemia (AML) undergoing HLA-haploidentical hematopoietic cell transplant (haploHCT) with a …
Learn More

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

S
Sandeep Batra, MD
All genders
Phase 3
Interventional
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acuteyeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either …
Learn More
11 - 20 of 28